PHENYLTRIAZOLE DERIVATIVE

摘要

Provided are novel compounds that are useful in the prevention or treatment of such diseases as dementia, Alzheimer's disease, attention-deficit hyperactivity disorder, schizophrenia, epilepsy, central convulsion, obesity, diabetes mellitus, hyperlipidemia, narcolepsy, idiopathic hypersomnia, behaviorally induced insufficient sleep syndrome, sleep apnea syndrome, circadian rhythm disorder, parasomnia, sleep related movement disorder, insomnia, depression, or allergic rhinitis, or pharmaceutically acceptable salts of such compounds. Specifically, there are provided phenyltriazole derivatives represented by the following formula (I) or pharmaceutically acceptable salts thereof:;Formula (I);;wherein ring P refers to a group represented by the following formula (II) or (III):;;Q refers to a group represented by the following formula (A) or (B):;

主权项

1. A compound represented by formula (I): [wherein ring P refers to a group represented by the following formula (II) or (III): Q refers to a group represented by the following formula (A) or (B): R1 is a hydrogen atom, a halogen atom, or C1-C6 alkyl; R2 is a hydrogen atom, hydroxy, cyano, carboxy, C1-C6 alkyl, C2-C7 alkanoyl, C1-C6 alkylsulfonyl (the C1-C6 alkyl, C2-C7 alkanoyl or C1-C6 alkylsulfonyl may be substituted by one to three groups selected from the group consisting of a halogen atom, hydroxy and C1-C6 alkoxy), C1-C6 alkoxy, C3-C7 cycloalkyl, C2-C7 alkoxycarbonyl (the C1-C6 alkoxy, C3-C7 cycloalkyl or C2-C7 alkoxycarbonyl may be substituted by one to three groups selected from the group consisting of a halogen atom, hydroxy, C1-C6 alkyl and C1-C6 alkoxy), —(CH2)n—C(═O)NR1AR1B, or —S(═O)2NR2AR2B; R1A and R1B, which may be the same or different, are each a hydrogen atom, C1-C6 alkyl or C3-C7 cycloalkyl, or R1A and R1B may be bonded together with the adjacent nitrogen atom to form a 3- to 7-membered saturated heterocyclic ring (the saturated heterocyclic ring being optionally substituted by one or two groups selected from the group consisting of a halogen atom and C1-C6 alkyl); n is 0 or 1; R2A and R2B, which may be the same or different, are each a hydrogen atom, C1-C6 alkyl or C3-C7 cycloalkyl, or R2A and R2B may be bonded together with the adjacent nitrogen atom to form a 3- to 7-membered saturated heterocyclic ring (the saturated heterocyclic ring being optionally substituted by one or two groups selected from the group consisting of a halogen atom and C1-C6 alkyl); R3 is a hydrogen atom or C1-C6 alkyl; R4 is C1-C6 alkyl (the C1-C6 alkyl may be substituted by one or two C3-C7 cycloalkyls) or C3-C7 cycloalkyl (the C3-C7 cycloalkyl may be substituted by one or two C1-C6 alkyls); and R5 and R6, which may be the same or different, are each C1-C6 alkyl or C3-C7 cycloalkyl, or R5 and R6 may be bonded together with the adjacent nitrogen atom to form a 3- to 7-membered saturated heterocyclic ring (the saturated heterocyclic ring being optionally substituted by one or two C1-C6 alkyls)] (provided that N,N-dimethyl-3-[4-(1H-1,2,4-triazol-1-yl)phenoxy]propan-1-amine is excluded) or a pharmaceutically acceptable salt thereof.